帮助 关于我们

返回检索结果

Multicenter Clinical Study for Evaluation of Efficacy and Safety of Transdermal Fentanyl Matrix Patch in Treatment of Moderate to Severe Cancer Pain in 474 Chinese Cancer Patients

查看参考文献34篇

Zhu Yulin 1   Song Guohong 1   Liu Duanqi 2   Xi Zhang 3   Liu Kuifeng 4   Zang Aihua 5   Ying Cheng 6   Cao Guochun 7   Jun Liang 8   Ma Xuezhen 9   Xin Ding 10   Wang Bin 11   Li Weilian 12   Hu Zuowei 13   Gang Feng 14   Huang Jiangjin 15   Xiao Zheng 16   Jiao Shunchang 17   Rong Wu 18   Jun Ren 1 *  
文摘 Objective: Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have been obtained. This study aimed to assess the efficacy and safety of the new system in Chinese patients with moderate to severe cancer pain. Methods: A total of 474 patients with moderate to severe cancer pain were enrolled in this study and were treated with the new transdermal fentanyl matrix patch (TDF) up to 2 weeks. All the patients were asked to record pain intensity, side effects, quality of life (QOL), adherence and global satisfaction. The initial dose of fentanyl was 25 g/h titrated with opioid or according to National Comprehensive Cancer Network (NCCN) guidelines. Transdermal fentanyl was changed every three days. Results: After 2 weeks. The mean pain intensity of the 459 evaluated patients decreased significantly from 5.63-1.26 to 2.03-1.46 (P<0.0001). The total remission rate was 91.29%, of which moderate remission rate 53.16%, obvious remission rate 25.49% and complete remission rate 12.64%. The rate of adverse events was 33.75%, 18.78% of which were moderate and 3.80% were severe. The most frequent adverse events were constipation and nausea. No fatal events were observed. The quality of life was remarkably improved after the treatment (P<0.0001). Conclusion: The new TDF is effective and safe in treating patients with moderate to severe cancer pain, and can significantly improve the quality of life.
来源 Chinese Journal of Cancer Research ,2011,23(4):317-322 【核心库】
关键词 Transdermal fentanyl matrix patch (TDF) ; Cancer pain ; Efficacy ; Safety ; Quality of life
地址

1. Department of Breast Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, 100142  

2. The PLA Military General Hospital of Beijing, Beijing, 100009  

3. No. 3 People’s Hospital of Chengdu, Chengdu, 610031  

4. The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080  

5. Hubei Cancer Hospital, Wuhan, 430079  

6. Jilin Cancer Hospital, Changchun, 130012  

7. Jiangsu Cancer Hospital, Nanjing, 210009  

8. The Affiliated Hospital of Medical College Qingdao University, Qingdao, 266003  

9. Qingdao Cancer Hospital, Qingdao, 266042  

10. Shanghai Huaihai Hospital, Shanghai, 200031  

11. Suzhou Municipal Hospital, Suzhou, 215001  

12. Tianjin People’s Hospital, Tianjin, 300121  

13. Wuhan Integrated TCM & Western Medicine Hospital, Wuhan, 430070  

14. Pu Ai Hospital of Wuhan City, Wuhan, 430070  

15. Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, 310009  

16. Zhejiang Cancer Hospital, Hangzhou, 310022  

17. The General Hospital of the People’s Liberation Army, Beijing, 100853  

18. Shengjing Hospital of China Medical University, Shenyang, 110004

语种 英文
文献类型 研究性论文
ISSN 1000-9604
学科 肿瘤学
文献收藏号 CSCD:4406493

参考文献 共 34 共2页

1.  Winslow M. Stories of cancer pain: a historical perspective. J Pain Symptom Manage,2005,29:22-31 CSCD被引 1 次    
2.  Portenoy R K. Opioid therapy for chronic nonmalignant pain: A review of the critical issues. J Pain Symptom Manage,1996,11:203-217 CSCD被引 5 次    
3.  Hrachya Nersesyan. Current approach to cancer pain management: Availability and implications of different treatment options. Ther Clin Risk Manag,2007,3:381-400 CSCD被引 2 次    
4.  Pergolizzi J. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract,2008,8:287-313 CSCD被引 19 次    
5.  Schug S A. Treatment principles for the use of opioids in pain of nonmalignant origin. Drugs,1991,42:228-239 CSCD被引 5 次    
6.  McQuay H. Opioids in pain management. Lancet,1999,353:2229-2232 CSCD被引 3 次    
7.  Pereira J. Equianalgesic dose ratios for opioids: a critical review and proposals for long‐term dosing. J Pain Symptom Manage,2001,22:672-687 CSCD被引 4 次    
8.  Muijsers R B. Transdermal fentanyl: An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs,2001,61:2289-2307 CSCD被引 12 次    
9.  Mystakidou K. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res,2001,21:2225-2230 CSCD被引 4 次    
10.  Murphy M. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol,2000,1:361-368 CSCD被引 1 次    
11.  Kongsgaard U E. Transdermal fentanyl for pain control in adults with chronic cancer pain. Eur J Pain,1998,2:53-62 CSCD被引 1 次    
12.  Ahmedzai S. Transdermal fentanyl in cancer pain. The TTS‐Fentanyl Multicentre Study Group. J Drug Dev,1994,6:93-97 CSCD被引 1 次    
13.  Ahmedzai S. Transdermal fentanyl versus sustained‐release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS‐Fentanyl Comparative Trial Group. J Pain Symptom Manage,1997,13:254-261 CSCD被引 14 次    
14.  Sloan P A. A clinical evalution of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage,1998,16:102-111 CSCD被引 4 次    
15.  Grond S. Transdermal fentanyl in the long‐term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain,1997,69:191-198 CSCD被引 2 次    
16.  Payne R. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol,1998,16:1588-1593 CSCD被引 6 次    
17.  Radbruch L. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med,2001,15:309-321 CSCD被引 5 次    
18.  Kornick C A. Benefit‐risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf,2003,26:951-973 CSCD被引 4 次    
19.  Sun Y. Guideline for cancer pain relief by three steps. 2nd ed,2002:100-101 CSCD被引 1 次    
20.  Gourlay G K. Treatment of cancer pain with transdermal fentanyl. Lancet Oncol,2001,2:165-172 CSCD被引 2 次    
引证文献 1 篇

1 程志祥(综述) 芬太尼透皮贴剂治疗癌痛的药理特点及其临床应用 中国肿瘤临床,2013,40(24):1495-1497
CSCD被引 0 次

显示所有1篇文献

论文科学数据集
PlumX Metrics
相关文献

 作者相关
 关键词相关
 参考文献相关

版权所有 ©2008 中国科学院文献情报中心 制作维护：中国科学院文献情报中心
地址：北京中关村北四环西路33号 邮政编码：100190 联系电话：(010)82627496 E-mail:cscd@mail.las.ac.cn 京ICP备05002861号-4 | 京公网安备11010802043238号